NasdaqCM - Nasdaq Real Time Price ? USD Alterity Therapeutics Limited (ATHE) Follow Compare 1.1790 -0.0310 (-2.56%) As of 10:49 AM EST. Market Open. All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434 – Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the peer-reviewed journal, Metallomics has published data on the importance of iron and iron-targeting agents like ATH434 to treat neurodeg GlobeNewswire ? yesterday ATHE -2.56% PRNAF Appendix 4C – Q1 FY25 Quarterly Cash Flow Report Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System AtrophyMultiple data presentations at the International Congress of Parkinson’s Disease and Movement Disorders? (MDS)Appointed Abby Macnish Niven as Chief Financial OfficerCash balance on 30 September 2024 of A$9.28m MELBOURN GlobeNewswire ? 7 days ago ATHE -2.56% PRNAF Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, 17 October 2024 at 1:30 p.m. ET in the United States / Friday, 18 Oc GlobeNewswire ? 24 days ago ATHE -2.56% PRNAF Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting MELBOURNE, Australia and SAN FRANCISCO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced promising new data related to ATH434 were presented at the Society for Neuroscience 2024 in Chicago, USA. The poster entitled, “Potent Antioxidant and Mitochondrial-protectant Effects of ATH434, a Novel Inhibitor of α-Synuc GlobeNewswire ? 27 days ago ATHE -2.56% PRNAF Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders? - ATH434 shows promise as a disease-modifying therapy for MSA - - ATH434-202 Phase 2 interim data demonstrate stabilization of clinical symptoms and biomarkers in clinical responders - MELBOURNE, Australia and SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presenta GlobeNewswire ? last month ATHE -2.56% PRNAF Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company’s Chief Financial Officer (CFO), effective today. “We look forward to Abby’s contributions whose broad experience and financial background will help us advance our programs. I GlobeNewswire ? last month ATHE -2.56% PRNAF Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders? - Late Breaking Abstract and Oral Presentation on ATH434-202 Interim Phase 2 Data - - Oral Presentation on ATH434-201 Phase 2 Baseline Characteristics - MELBOURNE, Australia and SAN FRANCISCO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that multiple oral and poster presentations will be presented at the GlobeNewswire ? last month ATHE -2.56% PRNAF Appendix 4C – Q4 FY24 Quarterly Cash Flow Report Highlights Positive interim data reported from ATH434-202 Phase 2 clinical trial showing improvement on the UMSARS Activities of Daily Living Scale and stable or improved neurological symptoms in some patientsData from the bioMUSE Natural History Study continues to characterize early stage MSA and inform Alterity’s Phase 2 clinical trialsMultiple data presentations at the World Orphan Drug Congress and the American Academy of Neurology (AAN) Annual MeetingCash balance on 30 June 2024 of A$12.6M GlobeNewswire ? 3 months ago ATHE -2.56% PRNAF Alterity Therapeutics to Present at MST Financial Webinar MELBOURNE, Australia and SAN FRANCISCO, July 24, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be presenting a webinar to investors and shareholders hosted by MST Financial on Thursday, 25 July 2024 at 8:30am AEST. CEO David Stamler will present the Company’s recent developments, including the recently announced interim data fo GlobeNewswire ? 3 months ago ATHE -2.56% PRNAF Alterity (ATHE) Up on Interim Data From Advance MSA Study Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises. Zacks ? 3 months ago ATHE -2.56% Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy – 43% of Participants Showed Improvement on the UMSARS Activities of Daily Living Scale – – 29% of Participants had Stable or Improved Neurological Symptoms – – Objective Biomarkers Demonstrated Improvement Consistent with Clinical Findings – – ATH434 was Well-Tolerated with No Safety Signals Detected – MELBOURNE, Australia and SAN FRANCISCO, July 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to develo GlobeNewswire ? 3 months ago ATHE -2.56% PRNAF Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar MELBOURNE, Australia and SAN FRANCISCO, June 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access ‘Hidden Gems in Life Sciences’ webinar on Thursday, 13 June 2024 in Australia / Wednesday, 12 June 2024 in the United State GlobeNewswire ? 4 months ago ATHE -2.56% PRNAF Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study - New bioMUSE Data Informs ATH434-202 Study Endpoints - - Webcast to Include Key Opinion Leader, Daniel Claassen, M.D., M.S., Vanderbilt University - MELBOURNE, Australia and SAN FRANCISCO, May 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast today on Thursday, 30 May 2024 in Australia / Wednesda GlobeNewswire ? 5 months ago ATHE -2.56% PRNAF Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review - ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH43 GlobeNewswire ? 5 months ago ATHE -2.56% PRNAF Appendix 4C – Q3 FY24 Quarterly Cash Flow Report Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s diseaseRaised approximately A$5.25M to strengthen the balance sheetReceived an A$3.9M Research and Development Tax Incentive RefundCash balance on 31 March 2024 of A$18.3M MELBOURNE, Australia and SAN FRANCISCO, April 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” GlobeNewswire ? 6 months ago ATHE -2.56% PRNAF Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia – New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron – MELBOURNE, Australia and SAN FRANCISCO, April 29, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that important new data on its lead drug candidate ATH434 was presented at the World Orphan Drug Congress USA 2024 in Boston, MA. The GlobeNewswire ? 6 months ago ATHE -2.56% PRNAF Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting – ATH434 Improved Motor Performance and General Function in a Primate Model of Parkinson’s Disease – – ATH434-201 Phase 2 Baseline Data Confirm Approach to Target Biomarkers for Slowing Disease Progression – – 12-Month Data from bioMUSE Study Shows Key Biomarker is Associated with Disease Progression in MSA – MELBOURNE, Australia and SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to GlobeNewswire ? 6 months ago ATHE -2.56% PRNAF Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 MELBOURNE, Australia and SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new data on ATH434 will be presented at the World Orphan Drug Congress USA 2024 taking place April 23-25, 2024 in Boston, MA. Title:Biophysical Characteristics of ATH434, a Unique Iron-Targeting Drug for Treating Frie GlobeNewswire ? 6 months ago ATHE -2.56% PRNAF Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received a A$3.9 million cash refund from the Australian Taxation Office under the Australian Government’s Research and Development Tax Incentive (R&DTI) Scheme. The cash refund relates to the cost of e GlobeNewswire ? 7 months ago ATHE -2.56% PRNAF Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting – Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease to be Presented at International Conference – – Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial – MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that thr GlobeNewswire ? 8 months ago ATHE -2.56% PRNAF Performance Overview Trailing total returns as of 11/7/2024, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] Return ATHE S&P/ASX 200 [XJO] YTD -52.65% +8.37% 1-Year -47.60% +17.90% 3-Year -90.26% +10.32%
